Probleme bei der Darstellung von ARIVA.DE?

  • Laden unsere Charts bei Ihnen nicht?
  • Wird unser Forum bei Ihnen nicht korrekt dargestellt?

Sie nutzen einen Adblocker, der hierfür verantwortlich ist. Hierauf hat ARIVA.DE leider keinen Einfluss. Bitte heben Sie die Blockierung von ARIVA.DE in Ihrem Adblocker auf.

Probleme bei der Darstellung von ARIVA.DE?


ROUNDUP: Gesundheitsgesetz gescheitert - Trump will sich Steuerreform zuwenden

Medicrea Releases Annual Sales for 2016

Donnerstag, 12.01.2017 20:20


The MEDICREA Group (Alternext Paris: FR0004178572 - ALMED), worldwide leader pioneering the development and manufacture of personalized analytical services and implant solutions for the treatment of complex spinal conditions, announces its 2016 annual sales.

€ millions   2015   2016   Δ

Year to date September 2016







4th Quarter




TOTAL   27.8   29.4   +6%

Variations in foreign currency rates had no significant impact on 2016 annual sales.


Group Sales reached a total of €29.4 million in 2016, generating a 6% growth compared to the previous year. 4th quarter sales increased 13% compared to the same period of 2015, in line with the accelerated adoption of Medicrea’s patient-specific UNiD™ technology, notably in the United States where for the entire year the number of surgeries performed with personalized rods implants have increased by 106% compared to 2015.

The 1,000th UNiD™ Rod milestone was achieved in November (almost 1,100 surgeries performed by the end of the year) closely tracking the launch of the company’s Lifetime Warranty on UNiD™ Rod constructs.

Next publication: 2016 annual results published March 29, 2017, after market.


MEDICREA specializes in bringing pre-operative digital planning and pre and post-operative analytical services to the world of complex spine. Through the lens of predictive medicine, MEDICREA leads the design, integrated manufacture, and distribution of 30+ FDA approved implant technologies, utilized in over 100k spinal surgeries to date. Operating in a $10 billion marketplace, MEDICREA is an SME with 160 employees worldwide, which includes 55 at its USA Corp. subsidiary in NYC. The Company has an ultra-modern manufacturing facility in Lyon, France housing the development and production of 3D-printed titanium patient-specific implants.

By leveraging its proprietary software analysis tools with big data and deep learning technologies supported by an expansive collection of clinical and scientific data, MEDICREA is well-placed to streamline the efficiency of spinal care, reducing procedural complications and limiting time spent in the O.R.

For further information, please visit:

Connect with MEDICREA:

Paris ISIN: FR 0004178572 –
Ticker: ALMED

View source version on

(c)Business Wire. All of the news releases contained herein are protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Business Wire's members, who warrant that they are solely responsible for the content, accuracy and originality of the information contained therein. All reproduction, other than for an individual user's personal reference, is prohibited without prior written permission.